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Purpose of the study
Darunavir (DRV) is an HIV protease inhibitor (PI) first
approved in 2006. This analysis evaluated the prevalence
of DRV resistance associated mutations (RAMs) in clini-
cal samples submitted for routine resistance testing to
assess potential changes or evolution in the frequency of
these mutations over time.
Methods
Annual prevalence of the IAS-USA 2009 DRV RAMs
(V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V,
I84V, and L89V) was studied in approximately 232,000
routine clinical samples submitted to Virco for resis-
tance testing between Jan 2003 and Dec 2009. Preva-
lence was assessed over time for individual DRV RAMs,
DRV RAM combinations and presence of 0, 1, 2, or ≥3
DRV RAMs. Results for DRV RAMs were expressed as
the proportion of (1) all clinical samples, (2) samples
with evidence of PI resistance (defined by FDA mutation
l i s t ,o rap r e d i c t e df o l dc h a n g e( F C )i nI C 5 0f o ra n yP I
greater than the respective virco®TYPE HIV-1 (VTY)
lower clinical cut-off [CCO] (FC=10) and (3) samples
with DRV resistance defined by predicted FC >10.
Summary of results
Overall prevalence of samples showing evidence of any
PI resistance decreased gradually over time (from 2003
to 2009: 47.0% to 32.2% [VTY lower CCO]; 49.1% to
42.2% [US-FDA mutation list]. Mean prevalence of each
of the 11 individual DRV RAMs also decreased over
time (Figure 1)
Prevalence of samples harbouring ≥1 DRV RAMs also
decreased over time. In 2009, 94.3% of all samples har-
boured zero DRV RAMs versus 85.3% in 2003. Among
samples with evidence of PI resistance, 88% vs 72% (per
FDA list) and 84% vs 70% (to any PI defined by pre-
dicted FC> low CCO) harboured zero DRV RAMs. The
most common three DRV RAM combination was L33F,
I54L,I84V which was detected with a prevalence of
0.15% in 2003 and 0.08% in 2009.
Conclusions
In 2009, most routine clinical HIV isolates (94.3%) har-
boured zero DRV RAMs. Despite widespread DRV use,
the prevalence of DRV RAMs among all clinical isolates
and among those with evidence of PI resistance has
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Figure 1 2009 IAS-USA DRV RAMs as a proportion of samples with
evidence of PI resistance by VTY lower CCO.
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gic suppression on the mutation rate and/or DRV’s high
genetic barrier to the development of resistance within
the treatment regimen.
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